Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Eagle Asset Management Inc.

Eagle Asset Management Inc. increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 130.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 624,759 shares of the biopharmaceutical company's stock after acquiring an additional 353,723 shares during the period. Eagle Asset Management Inc. owned approximately 0.59% of Intra-Cellular Therapies worth $45,714,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ITCI. Perceptive Advisors LLC grew its position in Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company's stock valued at $117,557,000 after acquiring an additional 661,052 shares in the last quarter. Millennium Management LLC boosted its position in Intra-Cellular Therapies by 214.5% in the 2nd quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company's stock valued at $60,895,000 after buying an additional 606,358 shares during the period. Avoro Capital Advisors LLC grew its stake in shares of Intra-Cellular Therapies by 21.2% in the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company's stock worth $205,470,000 after acquiring an additional 525,000 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Intra-Cellular Therapies during the second quarter worth $34,178,000. Finally, Hood River Capital Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the second quarter valued at $33,390,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, President Michael Halstead sold 22,869 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sharon Mates sold 34,396 shares of the company's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. The trade was a 3.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 97,778 shares of company stock worth $7,524,436. Insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ITCI shares. Morgan Stanley upped their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $130.00 target price on shares of Intra-Cellular Therapies in a report on Monday, September 16th. The Goldman Sachs Group lowered their price target on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a "neutral" rating for the company in a report on Thursday, August 8th. Royal Bank of Canada raised their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an "outperform" rating in a report on Friday, October 4th. Finally, Piper Sandler raised Intra-Cellular Therapies from a "neutral" rating to an "overweight" rating and increased their target price for the company from $68.00 to $92.00 in a report on Friday, September 6th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, Intra-Cellular Therapies presently has an average rating of "Moderate Buy" and an average price target of $97.23.

Intra-Cellular Therapies Trading Up 0.3 %

Shares of NASDAQ:ITCI traded up $0.24 during trading on Friday, hitting $85.69. 437,924 shares of the stock were exchanged, compared to its average volume of 770,578. Intra-Cellular Therapies, Inc. has a 12-month low of $58.14 and a 12-month high of $93.45. The company has a market cap of $9.08 billion, a PE ratio of -98.49 and a beta of 0.97. The company has a fifty day moving average price of $79.25 and a two-hundred day moving average price of $74.76.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. During the same period last year, the company posted ($0.25) EPS. The firm's revenue for the quarter was up 39.0% on a year-over-year basis. Equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.